Ryoncil's Strong Financial Debut
Mesoblast's Ryoncil Achieves US$115 Million First-Year Revenue, Exceeding Initial Projections
Key Points
Ryoncil is the only FDA-approved therapy for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD).
FY26 full-year net revenue reached US$115 million, exceeding the company’s initial projections and its guidance of US$110-120 million.
In its first full commercial half-year, Ryoncil generated US$49 million in revenue at a 93% gross margin.
A new five-year financing facility freed up capital that would otherwise have funded day-to-day operations, enabling management to direct resources toward label-extension studies and other strategic initiatives across the pipeline.
Market reaction included a drop in Mesoblast's stock price to around US$2.03 per share following the results.
Mesoblast's Ryoncil pulled in US$36 million in net revenue during the June quarter, capping a landmark first year of commercial sales at US$115 million — already above the company's own guidance of US$110–120 million, according to Kalkine and Finn News Network.
Ryoncil is the only FDA-approved therapy for children under 12 with steroid-refractory acute graft-versus-host disease, a rare and often fatal immune complication after bone marrow transplants. The strong debut revenue positions Mesoblast to fund new studies and push into adult markets — though shares still slipped to around US$2.03 following the results.
Ryoncil's First Year Smashes Early Sales Projections
Mesoblast launched Ryoncil commercially in the second half of FY26. In that first commercial half-year alone, the drug generated US$49 million in revenue at a 93% gross margin, according to ShareCafe. The full-year figure of US$115 million then beat the company's own projected range.
Management credited strong uptake across major U.S. pediatric transplant centers. Steroid-refractory acute graft-versus-host disease — when a patient's immune system attacks their own body after a transplant, and steroids fail to stop it — has no other approved treatment for young children. That leaves Ryoncil in a market with no direct competition.
New Financing Deal Frees Up Cash for Pipeline Growth
Mesoblast also secured a new five-year financing facility. Before the deal, operating cash came largely from the company's own reserves. Now that revenue is funding day-to-day operations, the financing frees up capital for label-extension studies and broader strategic moves, according to TipRanks.
The company plans to use this capital runway to explore Ryoncil's use in adult patients with the same condition — SR-aGvHD — as well as additional disease indications across its pipeline. Management described the combination of strong revenue and flexible financing as a meaningful shift in the company's financial footing.
What Comes Next: Adults, New Indications, and Wider Access
Mesoblast flagged continued revenue growth for FY27. The company is targeting adult SR-aGvHD patients, a larger potential market than the pediatric segment that drove FY26 sales. Expanding into that space would require further regulatory work, but management said it has the capital to pursue it, per Finn News Network.
The company also aims to broaden access at U.S. pediatric centers that have not yet adopted Ryoncil. With a first-year commercial track record now in place and a high gross margin, Mesoblast argues it has the financial base to grow the business without relying on equity raises, according to Kalkine.
Stock Slips Despite Record Revenue Beat
Despite the strong numbers, Mesoblast shares fell to around US$2.03 after the results were released. Biotechs often see this pattern — investors who expected even bigger results, or who are taking profits after a run-up, sell on the news even when results are solid, as noted by TipRanks.
Still, the revenue result marks a clear turning point for Mesoblast. For years the company burned cash while seeking FDA approval. Now, with US$115 million in first-year sales and a 93% gross margin, it has a commercial product generating real income — a rare milestone for a cell therapy company, according to Grafa.
Sentiment
Mostly PositivePublishers
12
Articles
4
Reach
16
